|1.||Schima, Wolfgang: 6 articles (12/2007 - 09/2002)|
|2.||Weill, Bernard: 5 articles (01/2014 - 02/2005)|
|3.||Batteux, Frédéric: 5 articles (01/2014 - 02/2005)|
|4.||Laurent, Alexis: 5 articles (01/2012 - 02/2005)|
|5.||Nicco, Carole: 4 articles (01/2014 - 02/2005)|
|6.||Ba-Ssalamah, Ahmed: 4 articles (12/2007 - 12/2002)|
|7.||Jynge, Per: 3 articles (04/2015 - 09/2007)|
|8.||Chéreau, Christiane: 3 articles (01/2014 - 02/2005)|
|9.||Alexandre, Jérôme: 3 articles (01/2014 - 02/2005)|
|10.||Schima, W: 3 articles (05/2006 - 01/2002)|
07/01/2003 - "A significant improvement in the liver-to-tumor contrast-to-noise ratio was observed with mangafodipir (p < 0.05, paired t test) in 0.5T preoperative images. "
09/01/1999 - "Qualitative image analysis demonstrated a significant improvement of manganese-DPDP-enhanced fat-suppressed MR images in delineating the pancreatic parenchyma (P < 0.01) as well as pancreatic tumors (P < 0.01). "
08/01/2000 - "This study indicates that a) MRI after mangafodipir trisodium gives a better delineation of the tumor in T1w series, but b) does not significantly improve the detection rate and staging accuracy of focal pancreatic lesions over MRI without this contrast medium."
01/01/1999 - "In our study, Mn-DPDP increased CNR of both benign and malignant tumors but did not enable differentiation between benign and malignant tumors of hepatocellular nature."
07/01/1996 - "Mn-DPDP-enhanced MR imaging depicts HCC tumors not visualized with unenhanced studies. "
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
05/01/2004 - "Recently, Mangafodipir-enhanced MR imaging using a whole-body coil has been shown to be effective in the detection and staging of pancreatic cancer . "
09/01/2002 - "Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT."
08/01/2000 - "MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer."
09/01/2002 - "Mangafodipir trisodium-enhanced MR imaging is as accurate as contrast-enhanced helical CT for the detection and staging of pancreatic cancer but offers improved detection of small pancreatic metastases and of liver metastases compared with CT."
01/01/2002 - "Recent studies have revealed that mangafodipir-enhanced MRI is at least equal to spiral CT in the staging of pancreatic cancer and may be superior to CT in the detection of small cancers. "
|3.||Hepatocellular Carcinoma (Hepatoma)
11/01/2008 - "To define histopathological factors related to the degree of mangafodipir trisodium (MnDPDP) uptake in hepatocellular carcinomas (HCCs) on magnetic resonance imaging (MRI). "
11/01/2008 - "Mangafodipir trisodium-enhanced MRI of hepatocellular carcinoma: correlation with histological characteristics."
04/01/2004 - "Mn-DPDP-enhanced 24-h delayed-scan MRI of hepatocellular carcinoma is correlated with histology."
05/01/2003 - "Multiple nodules in the liver parenchyma were differentiated from hepatocellular carcinoma by magnetic resonance imaging (MRI) using mangafodipir trisodium as a paramagnetic liver-specific contrast agent. "
08/01/1996 - "Uptake of mangafodipir trisodium (MnDPDP) by hepatocellular carcinoma: correlation with unenhanced imaging findings and histopathologic features."
|4.||Neoplasm Metastasis (Metastasis)
01/01/2009 - "Our purpose was to assess the diagnostic performance of MRI, before and after administration of mangafodipir trisodium (MnDPDP), in the detection of neuroendocrine liver metastases. "
07/01/2008 - "However, Mn-DPDP MRI is superior for small liver metastases and remains a prerequisite for surgical planning in patients with confined liver metastases."
07/01/2008 - "PETCT has high sensitivity and specificity for the presence of liver metastases and should be included early in initial pre-surgical evaluation and could potentially guide the use of Mn-DPDP MRI. "
07/01/2008 - "For liver metastases on a per-patient basis, the sensitivity and specificity of both PETCT and Mn-DPDP MRI were 98% and 100%, respectively. "
07/01/2008 - "Results were retrospectively reviewed for extrahepatic disease on PETCT and ceCT, and for the presence and number of liver metastases on PETCT and Mn-DPDP MRI. "
08/01/2000 - "One hour after the administration of Mn-DPDP, R1 in normal myocardium (1.53 sec(-1) +/- 0.03, 1.73 sec(-1) +/- 0.03, and 1.94 sec(-1) +/- 0.02, respectively, for 25, 50, and 100 micromol/kg) was significantly (P <.05) faster than that of reperfused infarction (0.99 sec(-1) +/- 0.03, 1.11 sec(-1) +/- 0.03, and 1.48 sec(-1) +/- 0.06). "
07/01/1989 - "Use of Mn-DPDP permitted delineation of the area of infarction. "
08/01/2000 - "Mn-DPDP-enhanced inversion-recovery echo-planar and SE MR images demonstrated retention of manganese in normal myocardium and clearance of manganese from infarction. "
08/01/2000 - "To assess whether normal myocardium can be distinguished from infarction at magnetic resonance (MR) imaging with low doses of manganese dipyridoxyl diphosphate (Mn-DPDP). "
|3.||Gadolinium DTPA (Magnevist)
|4.||gadobenic acid (gadobenate dimeglumine)
|5.||N,N'- bis(pyridoxal- 5- phosphate)ethylenediamine- N,N'- diacetic acid (mangafodipir)
|8.||gadolinium ethoxybenzyl DTPA
|2.||Drug Therapy (Chemotherapy)